Demographic and clinical characteristics of the patient cohort (N=101)
| Patient characteristics | |
|---|---|
| Age, years | 64 (54.5–71.5) |
| Sex, male/female, % | 53 (52.5)/48 (47.5) |
| Body mass index, kg/m2 | 25.4 (22.5–28.4) |
| Duration of diabetes, years | 8 (2–14.5) |
| SBP, mm Hg | 132 (121–144) |
| DBP, mm Hg | 77 (68–86) |
| PP, mm Hg | 55 (47–65) |
| Fasting plasma glucose, mg/dL | 157 (123.5–203.5) |
| HbA1c, % (mmol/mol) | 9.3 (8.1–10.7) (78 (65–93)) |
| Fasting insulin, µU/mL | 4.7 (2.2–8.3) |
| Total cholesterol, mg/dL | 194 (168.5–223.5) |
| HDL-C, mg/dL | 46.6 (39.9–57.8) |
| TG, mg/dL | 142 (114–197) |
| FFA, µEq/L | 704 (558–910) |
| Cre, mg/dL | 0.67 (0.58–0.83) |
| Ccr, mL/min | 106.6 (84.2–131.7) |
| Urinary albumin, mg/day | 9.3 (5.2–33.6) |
| Diabetes treatment | |
| Sulfonylurea, % | 50 (49.5) |
| Glinide, % | 0 (0) |
| Biguanide, % | 35 (34.7) |
| Thiazolidinedione, % | 13 (12.9) |
| α-Glucosidase inhibitor, % | 18 (17.8) |
| DPP-4 inhibitor, % | 54 (53.5) |
| SGLT2 inhibitor, % | 1 (1.0) |
Categorical variables are presented as a number (%) or median (lower quartile–upper quartile).
Ccr, creatinine clearance; Cre, creatinine; DBP, diastolic blood pressure; DPP-4, dipeptidyl peptidase-4; FFA, free fatty acids; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; PP, pulse pressure; SBP, systolic blood pressure; SGLT2, sodium glucose cotransporter 2; TG, triglycerides.